Report Scope:
The scope of this study encompasses an investigation of the cell and gene therapy market. BCC Research analyzes cell and gene therapy market based on therapy type, product, application, and region. BCC determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next five years. The report provides a detailed analysis of the market’s drivers, challenges, and opportunities. The report also covers market projections for 2028 and market shares for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on the emerging technologies, and new developments, ESG development and investment outlook.

Report Includes:

  • 55 data tables and 26 additional tables
  • An overview of the global market for cell and gene therapy
  • Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market’s size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region
  • An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR
  • Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years
  • Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook
  • Profiles of leading market participants, including Mallinckrodt PLC, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.